NR4A1 and neoplasm: As mentioned above, in breast cancer, a considerable number of tumours change their hormone receptor status at relapse or metastasis, thereby altering potential effective therapeutic strategies.25 In colorectal cancer, analysis of metastatic deposits revealed differences in specific mutations and protein expression, suggesting a molecular or pathway-driven treatment approach in place of, or in addition to, standard chemotherapy.26